Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.

What It Covers

This meta-analysis looks at Semaglutide and Glucagon.

Although trials have provided data about cardiovascular outcomes with this agent, a meta-analysis regarding its cardiovascular safety and variations in outcomes according to sex, race and estimated glomerular filtration rate was necessary.

Who the Included Studies Covered

PubMed tags the participants as both men and women.

How the Review Was Done

The researchers searched the PubMed, Cochrane Library, and Clinicaltrials.gov databases and included randomized controlled trials (RCTs) where semaglutide was the intervention and major adverse cardiovascular events (MACE) or expanded MACE was the outcome.

The researchers assessed the quality of the RCTs using the Cochrane Risk of Bias tool and used the statistical software RevMan 5.4.

The protocol for this review was registered on PROSPERO (CRD42024580784).

What Was Measured

Although trials have provided data about cardiovascular outcomes with this agent, a meta-analysis regarding its cardiovascular safety and variations in outcomes according to sex, race and estimated glomerular filtration rate was necessary.

PubMed files the paper under topics including Glucagon-Like Peptides, Cardiovascular Diseases, Hypoglycemic Agents, Randomized Controlled Trials as Topic, Sex Factors, Glomerular Filtration Rate and Diabetes Mellitus, Type 2.

What This Means in Plain Language

This is a meta-analysis of Semaglutide and Glucagon.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (American journal of cardiovascular drugs : drugs, devices, and other interventions), a journal based in New Zealand.

More context: the Semaglutide compound page and the Glucagon compound page, all human trials.